Economic Incentives and vDOT for Latent Tuberculosis Infection
Launched by JOHNS HOPKINS UNIVERSITY · Aug 20, 2021
Trial Information
Current as of June 26, 2025
Recruiting
Keywords
ClinConnect Summary
This clinical trial is studying a new way to help people complete their treatment for latent tuberculosis (TB), which is when a person is infected with TB but does not have symptoms or spread the disease. The study combines a method called Video Directly Observed Therapy (vDOT) with financial incentives. This means that participants will receive video support to help them take their medication as prescribed, along with some financial rewards for completing their treatment. The goal is to see if this approach works better than usual care in helping more people finish their TB treatment.
To be eligible for this trial, participants need to be at least 18 years old, live in the Baltimore area, and have been diagnosed with latent TB. They should also speak English or Spanish, or another language for which support is available. Participants will be prescribed a specific treatment regimen, such as Isoniazid/Rifapentine or Rifampin, and will be asked to follow the video instructions while also receiving incentives for completing their treatment. This trial is currently recruiting participants, and it offers a supportive way to help individuals manage their health effectively.
Gender
ALL
Eligibility criteria
- Inclusion Criteria:
- • 18 years old or older,
- • diagnosed with latent TB and determined to be appropriate for latent TB treatment by participants clinicians
- • reside in Baltimore metro area
- • speaks English or Spanish, or a language for which there is a short form available via the Johns Hopkins Medicine Institutional Review Board
- • prescribed 3 months Isoniazid/Rifapentine, prescribed 3 months Isoniazid/Rifampin, or 4 months Rifampin
- Exclusion Criteria:
- • younger than 18 years old
- • diagnosed with active TB
- • prescribed an alternative treatment regimen for latent TB
- • pregnant women (as determined by non-study directed clinical evaluation; BCHD performs urine pregnancy testing on women of child bearing age when indicated)
- • participant's spoken language does not have a translated long or short consent form
About Johns Hopkins University
Johns Hopkins University, a prestigious research institution located in Baltimore, Maryland, is renowned for its commitment to advancing medical science and public health through innovative clinical trials. With a rich history of groundbreaking research and a multidisciplinary approach, the university's clinical trial initiatives focus on translating scientific discoveries into effective treatments and interventions. Leveraging state-of-the-art facilities and a collaborative network of experts, Johns Hopkins University conducts rigorous clinical studies that aim to improve patient outcomes and address critical health challenges. Its dedication to ethical standards and participant safety underscores its role as a leader in clinical research.
Contacts
Jennifer Cobb
Immunology at National Institute of Allergy and Infectious Diseases (NIAID)
Locations
Baltimore, Maryland, United States
Baltimore, Maryland, United States
Patients applied
Trial Officials
Maunank Shah, MD, PhD
Principal Investigator
Johns Hopkins University
Timeline
First submit
Trial launched
Trial updated
Estimated completion
Not reported
Similar Trials